Winthrop Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$326K Sell
11,442
-1,218
-10% -$32.4K 0.08% 100
2026
Q2
$305K Buy
12,660
+85
+0.7% +$2.22K 0.07% 106
2026
Q1
$353K Buy
12,575
+422
+3% +$11.2K 0.09% 101
2025
Q4
$303K Sell
12,153
-1,833
-13% -$46.2K 0.07% 111
2025
Q3
$356K Sell
13,986
-1,007
-7% -$24.9K 0.09% 102
2025
Q2
$363K Sell
14,993
-17,367
-54% -$405K 0.09% 104
2025
Q1
$820K Sell
32,360
-228
-0.7% -$5.97K 0.23% 76
2024
Q4
$861K Buy
+32,588
New +$884K 0.23% 79
2024
Q1
– Sell
-19,302
Closed -$556K – 251
2023
Q4
$556K Buy
+19,302
New +$583K 0.18% 90

Other funds holding PFE

Winthrop Capital Management's PFE Position: Q3 2026 in Review

Winthrop Capital Management reduced its Pfizer (PFE) stake by 9.6% in Q3 2026, selling an estimated $32.4K and leaving 11,442 shares worth $326K. The position accounts for 0.08% of the portfolio, ranked #100.

Winthrop Capital Management first reported a position in PFE in Q4 2023 and has held it in 9 quarters since. The position peaked at $861K in Q4 2024. 2,908 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Winthrop Capital Management held 11,442 shares of Pfizer worth $326K as of Q3 2026.
  • Winthrop Capital Management sold 1,218 Pfizer shares in Q3 2026, an estimated $32.4K.
  • Pfizer made up 0.08% of Winthrop Capital Management's portfolio in Q3 2026, its #100 holding.
  • Winthrop Capital Management first reported a position in Pfizer in Q4 2023 and has held it in 9 quarters since.
  • Winthrop Capital Management's Pfizer position peaked at $861K in Q4 2024.
  • 2,908 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Winthrop Capital Management's 13F filing for Q3 2026, filed 5 Nov 2026.